Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mifomelatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Endevica Doses First Patient in Phase 2 Trial for Metastatic Colorectal Cancer
Details : TCMCB07 is a melanocortin‐3/4 antagonist peptide candidate in clinical development for the treatment of cachexia in patients with stage 4 metastatic colorectal cancer.
Product Name : TCMCB07
Product Type : Peptide
Upfront Cash : Inapplicable
April 17, 2025
Lead Product(s) : Mifomelatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TCMCB07
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Endevica Bio to Start Phase 2 Trial of Drug to Prevent Weight Loss in Cancer Patients
Details : TCMCB07 is a melanocortin‐3/4 antagonist peptide candidate in clinical development for the treatment of cachexia.
Product Name : TCMCB07
Product Type : Peptide
Upfront Cash : Inapplicable
December 20, 2024
Lead Product(s) : TCMCB07
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : A07D
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Endevica Bio Drug Candidate Shows Success in Weight Loss in New Study
Details : A07D is a first-in-class oral, MC4R agonist, peptide drug candidate, which is being evaluated in preclinical studies for the treatment of obesity.
Product Name : A07D
Product Type : Peptide
Upfront Cash : Inapplicable
April 23, 2024
Lead Product(s) : A07D
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TCMCB07
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TCMCB07 is melanocortin‐3/4 antagonist peptide candidate in designed to be first-in-class peptide drug with ability to cross blood-brain barrier and act on previously inaccessible target receptors to modulate body’s behavioral and metabolic response ...
Product Name : TCMCB07
Product Type : Peptide
Upfront Cash : Inapplicable
November 15, 2022
Lead Product(s) : TCMCB07
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TCMCB07
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Endevica Bio Doses First Patient in Phase 1 Clinical Trial of TCMCB07 for the Treatment of Cachexia
Details : TCMCB07 is melanocortin‐4 antagonist peptide candidate in reatment of cachexia, is designed to be first-in-class peptide drug with ability to cross BBB and act on previously inaccessible target receptors to modulate body’s behavioral and metabolic re...
Product Name : TCMCB07
Product Type : Peptide
Upfront Cash : Inapplicable
July 13, 2022
Lead Product(s) : TCMCB07
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TCMCB07
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TCMCB07 to be a first-in-class peptide drug. We are confident that its ability to cross the blood-brain barrier and act on previously inaccessible target receptors will be profoundly beneficial for patient outcomes.
Product Name : TCMCB07
Product Type : Peptide
Upfront Cash : Inapplicable
June 28, 2022
Lead Product(s) : TCMCB07
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TCMCB07
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Endevica’s lead compound, TCMCB07, describes unique mechanisms and properties of drug, specifically in treatment of cachexia, and potential for producing a platform for drug-like peptides based on the evidence.
Product Name : TCMCB07
Product Type : Peptide
Upfront Cash : Inapplicable
April 20, 2022
Lead Product(s) : TCMCB07
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TCMCB07
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Endevica Bio Reports TCMCB07 Preserves Lean Body Mass in Preclinical Cancer Cachexia Study
Details : TCMCB07 can preserve lean mass as well as attenuate muscle wasting and body weight loss during cancer cachexia. The authors concluded that TCMCB07 is a promising drug candidate with universal effects on treating cancer cachexia.
Product Name : TCMCB07
Product Type : Peptide
Upfront Cash : Inapplicable
August 31, 2021
Lead Product(s) : TCMCB07
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable